Citalopram in first episode schizophrenia: The DECIFER trial

[1]  M. Ruggeri,et al.  Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression , 2018, JAMA psychiatry.

[2]  L. Dixon,et al.  Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. , 2018, Annual review of clinical psychology.

[3]  B. Ardekani,et al.  Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis , 2018, JAMA psychiatry.

[4]  C. Correll,et al.  Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia , 2018, Acta psychiatrica Scandinavica.

[5]  S. Leucht,et al.  Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. , 2016, The American journal of psychiatry.

[6]  Alexander L. Miller,et al.  Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. , 2016, The American journal of psychiatry.

[7]  E. Chen,et al.  Impact of avolition and cognitive impairment on functional outcome in first-episode schizophrenia-spectrum disorder: a prospective one-year follow-up study , 2016, Schizophrenia Research.

[8]  Robert A Schoevers,et al.  The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. , 2015, Schizophrenia bulletin.

[9]  D. Rujescu,et al.  Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. , 2015, Schizophrenia bulletin.

[10]  R. Rosenheck,et al.  Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. , 2015, The American journal of psychiatry.

[11]  Lu Liu,et al.  Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis , 2014, Schizophrenia Research.

[12]  E. Castrén.  Neuronal network plasticity and recovery from depression. , 2013, JAMA psychiatry.

[13]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[14]  R. Howland,et al.  Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? , 2012, The American journal of medicine.

[15]  J. Suvisaari,et al.  Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. , 2012, Archives of general psychiatry.

[16]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[17]  A. Rush,et al.  The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder , 2008, Schizophrenia Research.

[18]  C. Fuchs,et al.  Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study , 2007, Psychopharmacology.

[19]  Se-Won Lim,et al.  Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder , 2006, Brain Research.

[20]  A. Cohen,et al.  The structure of negative symptoms within schizophrenia: implications for assessment. , 2006, Schizophrenia bulletin.

[21]  M. O'Neill,et al.  Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment , 2004, Neuroscience.

[22]  Larry Alphs,et al.  The InterSePT scale for suicidal thinking reliability and validity , 2003, Schizophrenia Research.

[23]  C. Fuchs,et al.  Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. , 2003, The American journal of psychiatry.

[24]  C. Fuchs,et al.  Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. , 2002, The American journal of psychiatry.

[25]  Eric J. Nestler,et al.  Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus , 2000, The Journal of Neuroscience.

[26]  D. Rubin.  Multiple Imputation After 18+ Years , 1996 .

[27]  M. Atkinson,et al.  A psychometric comparison of the Calgary depression scale for schizophrenia and the Hamilton depression rating scale , 1996, Schizophrenia Research.

[28]  R. Watts,et al.  Clinician’s Guide to Mind Over Mood , 1995, Journal of Cognitive Psychotherapy.

[29]  W. Vogel,et al.  Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. , 1989, Archives of general psychiatry.

[30]  曽良一郎,et al.  MATRICS Consensus Cognitive Battery(MCCB)日本語版の紹介 , 2009 .

[31]  S. Potkin,et al.  The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. , 2004, Schizophrenia bulletin.

[32]  J. Levine,et al.  SAFTEE: a technique for the systematic assessment of side effects in clinical trials. , 1986, Psychopharmacology bulletin.

[33]  W T Carpenter,et al.  The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. , 1984, Schizophrenia bulletin.